THERAPY DOSSIER · th-0143779df357

miR-101 delivered via adenoviral vector (Adv-miR-101)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32953883 ↗2020Reported benefit

The Effect of MicroRNA-101 on Angiogenesis of Human Umbilical Vein Endothelial Cells during Hypoxia and in Mice with Myocardial Infarction

MouseIschaemia-reperfusionCardiacC57BL/6n = 22 mice analysed: AMI+Adv-miR-101 (n=10, 3 died), AMI+Adv-n…Intramyocardial injection at three points in the left ventricular anterior wall infarct and peri-infarct areaInjected at the time of AMI induction during thoracotomy and coronary ligation…

Model: Acute myocardial infarction via left anterior descending coronary artery ligation

AgomiR-101 enhanced HUVEC proliferation, migration and tube formation in vitro via targeting EIF4E3 and activating HIF-1alpha/VEGF-A signalling; in vivo, adenoviral miR-101 delivery to infarcted myocardium significantly improved left ventricular ejection fraction and fractional shortening, reduced…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…